Non-small cell cancer
Gefitinib for advanced non small cell lung cancer
... lung cancer do not live longer when treated with gefitinib when compared with no other treatment or ...lung cancer has worsened after initial therapy, gefitinib may prolong the time before the cancer ...
270
Crizotinib in non small cell lung cancer
... metastatic non-small cells lung cancer ...activating cancer cells led to the iden- tification of a new targeted therapy such as Cri- ...The small molecule Crizotinib is a selec- tive ...
5
In vivo selection for spine-derived highly metastatic lung cancer cells is associated with increased migration, inflammation and decreased adhesion
... lung cancer, in which the vertebral column is the most frequently affected region ...lung cancer metastasis to the spine have been poorly ...by non-invasive, real-time ...lung cancer cells. In ...
13
An immunohistochemical study of cyclin dependent kinase 5 (CDK5) expression in non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker
... in cancer is ...in cancer tissue ...prostate cancer, breast cancer, medullary thyroid carcinoma, pituitary adenoma, and hepatocellular carcinoma, and CDK5 gene amplification was found in lung ...
8
Vaccines in Non Small Cell Lung Cancer
... Programmed death-1 (PD-1) protein is a T-cell receptor that interacts with 2 ligands, PD-L1 and PD-L2 ex- pressed by tumor cells, stromal cells, or both where an immunosuppressive action is produced [47]. The ...
6
1 2B adenosine receptor and cancer 2
... with non-small cell lung cancer, breast cancer, ovarian cancer, colorectal and six other types of cancers.. 473.[r] ...
23
Emerging therapies for non-small cell lung cancer
... Dacomitinib is a selective and irreversible inhibitor for EGFR [36, 37]. In 2014, an official announcement from Pfi- zer indicated the trial failure of dacomitinib in patients with refractory advanced ...
24
Superior vena cava syndrome in a patient with locally advanced lung cancer with good response to definitive chemoradiation: a case report
... Case presentation: Our patient was a 51-year-old black woman with locally advanced, stage IIIB non-small cell lung cancer who had no clinical symptoms of superior vena cava syndrome at the ...
6
Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer
... right paratracheal, prevascular, subcarinal and right hilar regions. The CT scan showed no evidence of interstitial lung disease. Histological analysis confirmed poorly dif- ferentiated adenocarcinoma. ...
5
Pathological transition as the arising mechanism for drug resistance in lung cancer
... SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large cell carcinoma; TTF1: thyroid ...
13
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation
... hilar lymphadenopathy. The detection of new breakthrough lesions while on pembrolizumab dictated the need for a re- biopsy of the new disease. Surprisingly, pathology revealed richly cellular malignant cells with ...
6
An adherent subline of a unique small cell lung cancer cell line downregulates antigens of the neural cell adhesion molecule
... lung cancer (SCLC) lines are distinguished from non-small-cell lung cancer (NSCLC) lines by their growth in floating aggregates, in contrast to the adherent monolayers formed by NSCLC ...
8
Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development and Therapy
... inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells. 1005[r] ...
36
Cell-free DNA in non-small cell lung cancer
... lung cancer screening, the authors described a pooled speci- ficity of 77% and sensitivity of 80%, and deduced that cfDNA alone is not suggested for lung cancer screening because of its rather low ...
7
Original Article The identification of genes associated with NSCLC prognosis based on an integrated bioinformatics analysis
... pancreatic cancer and correlated with patients’ poor prognosis ...resected non-small-cell lung cancer stage I-IIIA, a pre- liminary report by immunohistochemical assay ...in ...
8
Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells
... cervical cancer cell lines, HeLa and Siha, an ovarian cancer cell line, SKOV3, and a non-small cell lung cancer cell line, A549, were treated with ...
8
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
... (NSCLC): non-small cell lung cancer; (SCLC): small cell lung cancer; (TQ): Thymoquinone; (EAC): Ehrlic ascites sarcoma; (CDDP): Cisplatin; (PLKs): Polo like kinases; ...
11
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
... NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; EMT: epithelial-mesenchymal transition; 16HBE: normal human bronchial epithelial cells; LC-MS/MS: liquid ...
16
Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients
... First-line chemotherapy included cisplatin or carboplatin in combination with one of the following agents: pemetrexed (nonsquamous histology), vinorelbine, gemcitabine, or pacli- taxel. Patients who received pemetrexed ...
8
Surgical treatment in non small cell lung cancer with pulmonary oligometastasis
... The 21 inclusive patients were divided into two groups, the surgery group and the chemotherapy group. Routine preoperative checkups were done, including laboratory assessments of the blood cell count, serum ...
5